ClinicalTrials.gg
Active, not recruitingNCT06044350Updated Oct 2, 2026

A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders

A Phase 2 interventional study of BAT4406F Injection and BAT4406F Placebos in Optic Neuromyelitis Spectrum Disease, sponsored by Bio-Thera Solutions. Active, not recruiting at 45 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Bio-Thera Solutions · Phase 2, Interventional, and Treatment

Updated Oct 2, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
162
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a phase II/III multicenter, randomized, double-blind, placebo-controlled study, to investigate the efficacy and safety of BAT4406F injection in patients with neuromyelitis optica lineage disease (NMOSD) who are positive for aquaporin 4 antibody (AQP4-IgG) .

Read the detailed description

This study was a phase II/III multicenter, randomized, double-blind, placebo-controlled study, which was divided into screening period (4 weeks) , randomized control period (RCP) , and open-label period (Olp)A total of 162 subjects were enrolled during the screening period and randomly assigned 2:1 to either the BAT4406F group or the placebo group after randomization on Day 1 of the RCP, subjects would receive BAT4406F (at a dose of 500mg) or placebo, intravenously, at D 1 and D 182, respectively.

If any of the following conditions occur, subjects can enter OLP from RCP: 1. Subjects who complete the 52-week RCP study without recurrence of NMOSD can enter Olp within 14 days after the end of the RCP study. 2. In the stage of RCP, NMOSD recurred. After rescue therapy, the patients with stable condition could enter OLP within 28 days after diagnosis. Subjects continued to participate in the RCP study if they were not identified by CEC as having a relapse upon examination. 3. When a protocol-defined first relapse event of 35 cases is observed, or when all 162 subjects have completed randomization and 12 months have elapsed since the first dose in the last of these subjects, or when recommended by the Independent Data Monitoring Committee (IDMC) , the RCP study should be stopped for enrolled subjects, and all enrolled subjects at the RCP stage should stop the RCP study within 14 days of entry into OLP, after which subjects will receive BAT4406F injection at the same dose as RCP, at d 1 of OLP. After termination of the RCP study with BAT4406F every 6 months, subjects were given the option of enrolling in the OLP study.

02

Conditions studied

  • Optic Neuromyelitis Spectrum Disease
03

In context

Lead sponsor

Bio-Thera Solutions is the lead sponsor of 57 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age greater than or equal to the age of 18 and less than or equal to 65 patients, gender not limited;
  2. Met the 2015 international NMO diagnostic panel (IPND) criteria for NMOSD, And AQP4-IGG positive patients
  3. Screening before 2 times at least 2 years experience with clinical records of relapse,or experienced at least 1 clinically documented recurrence within 1 year prior to screening
  4. For subjects who had a relapse before screening, symptoms needed to be stable for at least 4 weeks before randomization
  5. Into the group of former dosage of under 30 mg and prednisone equivalent,and the trial drug must be used within a month after the withdrawal of hormones
  6. The score of EDSS 7 or less
  7. Has the fertility of men and women must agree during treatment and 6 months after the last dose of using effective method;
  8. Agreed to participate in trials, and books to sign the

Exclusion criteria

Exclusion Criteria:

  1. CD19 + b-cell count below the lower limit of normal, b-cell-scavenger drugs used 6 months before baseline or within 5 half-lives of the drug, whichever is older (including but not limited to Rituximab, enalizumab, etc.) ;
  2. 6 months prior to the baseline used other monoclonal antibody therapy;Baseline used within five half-life before other biological preparation;
  3. Used it for 3 months prior to the baseline McCaw phenol ester, azathioprine and methotrexate;6 months prior to the baseline using cyclophosphamide;Baseline before five half-life
  4. Within a month before the filter used intravenous immunoglobulin (IVIG), plasma exchange (PE);
  5. Within 4 weeks before screening received vaccine or live attenuated;Within 2 weeks before the baseline received inactivated vaccine;Baseline received within 4 weeks before the new coronavirus vaccine
  6. In another clinical study and the baseline from the test drug treatment under three months or 5 half-life of the drug (the long time limit shall prevail);
  7. This test for monoclonal antibody has a history of allergies, known in drug allergy patients;Serious drug allergy or for two or over two kinds of food or drugs;
  8. 6 months prior to screening, except NMOSD need continuous oral or intravenous dose > 20 mg/day of any more than 21 days
  9. Abnormal liver, kidney and bone marrow reserve
  10. positive at HIV history or enrollment screening; History of Andor or Hepatitis B surface antigen (HBSAG) positivity at screening [ or Hepatitis B core antibody positive, hepatitis B surface antibody negative, Hepatitis B virus deoxynucleotides (HBV DNA) quantification exceeding normal range ] ; Or Hepatitis C virus (HCV) antibody positive [ with HCV-rna quantitation exceeding the normal range ] , Treponema pallidum antibody positive at the time of enrollment;
  11. Comply with any of the following subjects a latent or active TB infection related standards:

    1. Current or past people with active TB;
    2. In history and/or physical examination during filter tip physical signs or symptoms of active TB;
    3. Recent close contact with people with active TB;
    4. At the time of screening, the positive result of TB infected T cells was found. A test could be repeated if the subject's first tb-infected t-cell test result was inconclusive, and the patient was excluded from this study if the test result was inconclusive (or positive) again.
  12. Covid-19 infection was diagnosed with clinical symptoms or signs consistent with 2019 coronavirus (COVID-19) infection (eg, fever, dry cough, dyspnea, sore throat, and fatigue) within 4 weeks before screening or during screening, or upon appropriate laboratory testing (at the discretion of the investigator or in accordance with local regulations) . If COVID-19 infection is confirmed before screening, appropriate laboratory testing is required to confirm that the infection has been cured;
  13. Suffering from metabolic, hematological, renal, hepatic, pulmonary, neuroendocrine, cardiac, infectious, gastrointestinal or other diseases, the researchers believe there is an unacceptable risk to patients, or it may affect NMOSD assessment;
  14. According to the researchers, there was a history of drug and alcohol abuse (drinking 14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 125 mL of wine) in the 12 months before screening;
  15. Subjects who are unable to undergo an MRI scan (for example, are allergic to Gd-containing MRI contrast media, have a pacemaker, defibrillator, or other metallic object with internal or external limitations to performing an MRI scan) ;
  16. Pregnant or lactating women, and screening or baseline pregnancy test positive female subjects;
  17. Researchers think that the other does not fit to participate in this study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
162 participants (estimated)

Study arms

  • Experimental
    Experimental group:BAT4406F

    RCP:Intravenous infusion; Dosage:500mg/time; Time of administration:The drug was given at D 1 and D 182 respectively OLP:Intravenous infusion; Dosage:500mg/time; Time of administration: After D1 dosing, Every 6 months to 1 times

    Drug: BAT4406F Injection

  • Active comparator
    Control group:BAT4406F Placebos

    RCP:Intravenous infusion; Dosage:500mg/time; Time of administration:The drug was given at D 1 and D 182 respectively OLP:Intravenous infusion; Dosage:500mg/time; Time of administration: After D1 dosing, Every 6 months to 1 times

    Drug: BAT4406F Placebos

Interventions

  • Intravenous infusion; Dosage:500mg/time

  • DrugBAT4406F Placebos

    Intravenous infusion; Dosage:500mg/time

06

What researchers measure

Primary outcomes

  1. Pharmacodynamics

    The follow-up time point of peripheral blood before and after the analysis to the medicine CD19 + B lymphocytes proportion/count change

    Time frame: RCP: Day7, Day14, Day28, Day56, Day84, Day112, Day140, Day182, Day280, Day364. OLP:D7, D28, Day84, Day182, Day280, Day364. Week 40+26n (n=1, 2, 3.....) , Week 52+26n (n=1, 2, 3.....). And OLP maximum period for 3 years

  2. Pharmacodynamics

    Serum immunoglobulin (IgG and IgM) levels were measured.

    Time frame: RCP:in Day84、Day182、Day280、Day364. OLP: in Day1、Day84、Day182、Day280、Day364 of every years.And OLP maximum period for 3 years

  3. Pharmacodynamics

    AQP4-IgG levels were measured.

    Time frame: RCP:in Day84、Day182、Day280、Day364. OLP: in Day1、Day84、Day182、Day280、Day364 of every years.And OLP maximum period for 3 years

  4. Pharmacokinetics(PK)

    Cmax

    Time frame: Through study completion,up to 49 months. And OLP maximum period for 3 years.

  5. Pharmacokinetics(PK)

    Tmax

    Time frame: Through study completion,up to 49 months. And OLP maximum period for 3 years.

  6. Pharmacokinetics(PK)

    Cmin

    Time frame: Through study completion,up to 49 months. And OLP maximum period for 3 years.

  7. Pharmacokinetics(PK)

    AUC0-tau

    Time frame: Through study completion,up to 49 months. And OLP maximum period for 3 years.

  8. Pharmacokinetics(PK)

    t1/2

    Time frame: Through study completion,up to 49 months. And OLP maximum period for 3 years.

  9. Pharmacokinetics(PK)

    CL

    Time frame: Through study completion,up to 49 months. And OLP maximum period for 3 years.

  10. Pharmacokinetics(PK)

    Vd

    Time frame: Through study completion,up to 49 months. And OLP maximum period for 3 years.

  11. Immunogenicity evaluation

    Resistant antibody positive rate (ADA)

    Time frame: RCP:in Day84、Day181、Day252、Day364. OLP: in Day84、Day181、Day252、Day364 of every years.And OLP maximum period for 3 years

  12. Immunogenicity evaluation

    The titers of Ada positive samples

    Time frame: RCP:in Day84、Day181、Day252、Day364. OLP: in Day84、Day181、Day252、Day364 of every years.And OLP maximum period for 3 years

Secondary outcomes

  1. Vital signs

    Number of participants with abnormal vital signs

    Time frame: Through study completion,up to 49 months. And OLP maximum period for 3 years.

  2. physical examination

    Number of participants with abnormal physical examination findings

    Time frame: Through study completion,up to 49 months. And OLP maximum period for 3 years.

  3. Laboratory tests

    Number of participants with abnormal laboratory test results

    Time frame: Through study completion,up to 49 months. And OLP maximum period for 3 years.

  4. electrocardiogram( ECG )

    Number of participants with abnormal ECG readings

    Time frame: Through study completion,up to 49 months. And OLP maximum period for 3 years.

  5. Adverse events(AE)

    Adverse events (AE) is happening, is happening because of adverse events leading to withdrawal Adverse events associated with drugs The occurrence of Serious adverse events (SAE)

    Time frame: Through study completion,up to 49 months. And OLP maximum period for 3 years.

  6. Injection site reactions

    Number of participants with injection site reactions

    Time frame: Through study completion,up to 49 months. And OLP maximum period for 3 years.

07

Study locations

45 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Aug 2023 (actual). Primary completion is estimated for Dec 2027, 52 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion May 2026 → Dec 2027 and completion May 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2023
First posted
Sep 21, 2023
StartActual
Aug 1, 2023
Primary completionEst.
Dec 31, 2027was May 2026
CompletionEst.
Dec 31, 2027was May 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
May 31, 2026→Dec 31, 2027
Oct 2, 2026
Study completion
May 31, 2026→Dec 31, 2027
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Primary completion May 31, 2026→Dec 31, 2027
    Study completion May 31, 2026→Dec 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06044350
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Aug 1, 2023
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 2, 2026

Study contacts

Xiangjun Chen, Doctor
principal investigator · Huashan Hospital
Chunfeng Liu, Doctor
principal investigator · Second Affiliated Hospital of Suzhou University
Qun Xue, Doctor
principal investigator · First Affiliated Hospital of Suzhou University
Yan Jiang, Doctor
principal investigator · Anhui Provincial Hospital
Yuying Zhao, Doctor
principal investigator · Shandong University Qilu Hospital
Li Guo, Doctor
principal investigator · Second Hebei Medical University Hospital
Meini Zhang, Doctor
principal investigator · The First Affiliated Hospital of Shanxi Medical University
Huan Yang, Doctor
principal investigator · The Central South University Xiang Ya Hospital
Daishi Tian, Doctor
principal investigator · Tongji hospital affiliated to Tongji Medical College
Yuming Xu, Doctor
principal investigator · The First Affiliated Hospital of Zhengzhou University
Jianglong Tu, Doctor
principal investigator · Second Affiliated Hospital of Nanchang University
Wei Qiu, Doctor
principal investigator · The third hospital affiliated to sun yat-sen university
Yamei Tang, Doctor
principal investigator · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Honghao Wang, Doctor
principal investigator · The First People's Hospital of Guangzhou
Xiaoling Luo, Doctor
principal investigator · Shenzhen city people's hospital
Aiyu Lin, Doctor
principal investigator · First Affiliated Hospital of Fujian Medical University
Chunming Xie, Doctor
principal investigator · China University Hospital of Southeast University
Xiang Li, Doctor
principal investigator · The first hospital affiliated to wenzhou medical college
Lan Tan, Doctor
principal investigator · Qingdao City Hospital
Fudong Shi, Doctor
principal investigator · Tianjin Medical University General Hospital
Juming Yu, Doctor
principal investigator · Affiliated Hospital of North Sichuan Medical College
Jun Guo, Doctor
principal investigator · The Second Affiliated Hospital of the PLA Air Force Military Medical University
Jiewen Zhang, Doctor
principal investigator · Henan Provincial People's Hospital
Yanghua Tian, Doctor
principal investigator · The Second Hospital of Anhui Medical University
Jing Ding, Doctor
principal investigator · Shanghai Zhongshan Hospital
Ping Chen, Doctor
principal investigator · Xianyang yanan university hospital co., LTD
Zunbo Li, Doctor
principal investigator · Xi'an high-tech Hospital Co. , Ltd.
Qihe Dai, Doctor
principal investigator · Jingzhou city central hospital
Dan Liu, Doctor
principal investigator · the first hospital of Baotou medicine college
Junyan Liu, Doctor
principal investigator · Hebei Medical University Third Hospital
Yiqi Wang, Doctor
principal investigator · Zhejiang Province People's Hospital
Bo Hu, Doctor
principal investigator · Xiehe hospital affiliated to tongji medical college
Yanbing Han, Doctor
principal investigator · First Affiliated Hospital of the Kunming Medical University
Feng Wang, Doctor
principal investigator · Wuxi city people's hospital
Zhanhua Liang, Doctor
principal investigator · The First Affiliated Hospital of Dalian Medical University
Weihe Zhang, Doctor
principal investigator · Sino-Japanese Friendship Hospital
Xiangyang Zhu, Doctor
principal investigator · Nantong First People's Hospital
Xinfeng Liu, Doctor
principal investigator · The Chinese people's liberation army general hospital in eastern theater
Weidong Pan, Doctor
principal investigator · Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Wei Lu, Doctor
principal investigator · The Central South University Xiang YA II hospital
Huiyu Feng, Doctor
principal investigator · The first hospital affiliated to sun yat-sen university
Feng Gao, Doctor
principal investigator · The first hospital of Peking University
Yun Xu, Doctor
principal investigator · Drum tower hospital affiliated to nanjing university school of medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BAT4406F

Start the discussion